================================================================================
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                    FORM 10-Q

              [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                For the quarterly period ended September 30, 2000

                                       OR

             [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                        For the transition period from to

                           Commission File No. 0-20260
                           Commission File No. 1-11440

                            INTEGRAMED AMERICA, INC.
             (Exact name of Registrant as specified in its charter)


              Delaware                                   06-1150326
    (State or other jurisdiction            (I.R.S. employer identification no.)
    of incorporation or organization)


        One Manhattanville Road
           Purchase, New York                                10577
 (Address of principal executive offices)                 (Zip code)


                                 (914) 253-8000
              (Registrant's telephone number, including area code)

         Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
Registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days.


               Yes [X]                   No [  ]

         The aggregate number of shares of the Registrant's  Common Stock,  $.01
par value, outstanding on November 1, 2000 was 3,813,557.

================================================================================

<PAGE>


                            INTEGRAMED AMERICA, INC.
                                    FORM 10-Q

                                TABLE OF CONTENTS


                                                                            PAGE

PART I  -   FINANCIAL INFORMATION

    Item 1. Financial Statements

               Consolidated Balance Sheets at September 30, 2000 (unaudited)
                 and December 31, 1999........................................ 3

               Consolidated Statements of Operations for the three and
                 nine-month periods ended September 30, 2000 and
                 1999 (unaudited)............................................. 4

               Consolidated Statements of Cash Flows for the nine-month
                 periods ended September 30, 2000 and 1999 (unaudited)........ 5

               Notes to Consolidated Financial Statements (unaudited)....... 6-7

    Item 2. Management's Discussion and Analysis of Financial Condition and
               Results of Operations....................................... 8-11

    Item 3. Quantitative and Qualitative Disclosures About Market Risk........11


PART II -   OTHER INFORMATION

    Item 1. Legal Proceedings.................................................12

    Item 2. Changes in Securities.............................................12

    Item 3. Defaults upon Senior Securities...................................12

    Item 4. Submission of Matters to a Vote of Security Holders...............12

    Item 5. Other Information.................................................12

    Item 6. Exhibits and Reports on Form 8-K..................................12


SIGNATURES  ..................................................................13

INDEX TO EXHIBITS ............................................................14

                                      -2-

<PAGE>


PART I -- FINANCIAL INFORMATION
    Item 1.      Consolidated Financial Statements
<TABLE>

                            INTEGRAMED AMERICA, INC.
                           CONSOLIDATED BALANCE SHEETS
              (all dollars in thousands, except per share amounts)
                                     ASSETS
<CAPTION>
                                                                                               September 30,      December 31,
                                                                                               -------------      ------------
                                                                                                   2000               1999
                                                                                               -------------      ------------
                                                                                                (unaudited)
Current assets:
<S>                                                                                                <C>              <C>
  Cash and cash equivalents ....................................................................   $ 4,182          $ 3,650
  Patient accounts receivable, less allowance for doubtful accounts of $1,117 and $851
    in 2000 and 1999, respectively..............................................................    10,445           10,460
  Business Service fees receivable, less allowance for doubtful accounts of $150 and $0
    in 2000 and 1999, respectively..............................................................       591              890
  Other current assets .........................................................................     1,357            1,162
                                                                                                   -------          -------
      Total current assets......................................................................    16,575           16,162
  Fixed assets, net ............................................................................     5,067            5,965
  Intangible assets, net........................................................................    17,990           18,163
  Other assets..................................................................................       358              525
                                                                                                   -------          -------
      Total assets..............................................................................   $39,990          $40,815
                                                                                                   =======          =======

                                                LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
  Accounts payable..............................................................................   $ 1,731          $ 1,080
  Accrued liabilities...........................................................................     3,102            2,948
  Due to Medical Practices......................................................................     3,063            1,768
  Current portion of long-term notes payable and other obligations..............................     1,132            1,691
  Patient deposits..............................................................................     2,846            2,970
                                                                                                   -------          -------
      Total current liabilities.................................................................    11,874           10,457
                                                                                                   -------          -------
Long-term notes payable and other obligations...................................................     2,719            3,719
                                                                                                   -------          -------
Shareholders' equity:
  Preferred  Stock,  $1.00 par value - 3,165,644  shares  authorized in 2000 and
    1999,  2,500,000  undesignated;   665,644  shares  designated  as  Series  A
    Cumulative  Convertible of which 165,644 shares were issued and  outstanding
    in 2000 and
    1999, respectively..........................................................................       166              166
  Common Stock, $.01 par value -  50,000,000 shares authorized in 2000 and 1999;
    and 5,413,571 and 5,368,960  shares issued in 2000 and 1999, respectively...................        54               54
  Capital in excess of par .....................................................................    54,182           54,140
  Accumulated deficit ..........................................................................   (24,131)         (25,230)
  Treasury Stock, at cost - 1,499,113 and 746,863 shares in 2000 and 1999, respectively.........    (4,874)          (2,491)
                                                                                                   -------          -------
      Total shareholders' equity ...............................................................    25,397           26,639
                                                                                                   -------          -------
      Total liabilities and shareholders' equity................................................   $39,990          $40,815
                                                                                                   =======          =======
</TABLE>

        See accompanying notes to the consolidated financial statements.

                                      -3-
<PAGE>

<TABLE>

                            INTEGRAMED AMERICA, INC.
                      CONSOLIDATED STATEMENTS OF OPERATIONS
              (all amounts in thousands, except per share amounts)

<CAPTION>

                                                                  For the                   For the
                                                            three-month period        nine-month period
                                                            ended September 30,       ended September 30,
                                                           --------------------       --------------------
                                                              2000       1999           2000       1999
                                                           --------   ---------       ---------  ---------
                                                                (unaudited)               (unaudited)

<S>                                                          <C>         <C>             <C>        <C>
Revenues, net ............................................   $14,810     $11,862         $41,945    $33,255

Cost of services incurred:
   Employee compensation and related expenses.............     5,441       4,620          15,908     12,883
   Direct materials.......................................     3,267       1,785           8,428      4,091
   Occupancy costs........................................       827         766           2,487      2,674
   Depreciation...........................................       307         402             986      1,011
   Other expenses.........................................     2,536       1,899           7,655      5,373
                                                             -------     -------         -------    -------
     Total cost of services rendered......................    12,378       9,472          35,464     26,032
                                                             -------     -------         -------    -------

Contribution..............................................     2,432       2,390           6,481      7,223

General and administrative expenses.......................     1,642       1,611           4,381      4,504
Amortization of intangible assets.........................       216         274             650        779
Interest income...........................................       (56)        (46)           (141)       (88)
Interest expense..........................................       109         121             328        382
                                                             -------     -------         -------    -------
   Total other expenses...................................     1,911       1,960           5,218      5,577

Income before income taxes................................       521         430           1,263      1,646
Provision for income taxes................................        81          45             165        217
                                                             -------     -------         -------    -------

Net income................................................       440         385           1,098      1,429
Less: Dividends paid and/or accrued on Preferred Stock....        33          33              99         99
                                                             -------     -------         -------    -------
Net income applicable to Common Stock.....................   $   407     $   352         $   999    $ 1,330
                                                             =======     =======         =======    =======
Basic earnings per share of Common Stock..................   $  0.10     $  0.07         $  0.24    $  0.27
                                                             =======     =======         =======    =======
Diluted earnings per share of Common Stock................   $  0.10     $  0.07         $  0.23    $  0.27
                                                             =======     =======         =======    =======

Weighted average shares - basic...........................     4,059       4,863           4,199      4,910
                                                             =======     =======         =======    =======
Weighted average shares - diluted.........................     4,119       4,981           4,261      5,002
                                                             =======     =======         =======    =======


</TABLE>

        See accompanying notes to the consolidated financial statements.

                                       -4-

<PAGE>

<TABLE>


                            INTEGRAMED AMERICA, INC.
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                           (all amounts in thousands)
<CAPTION>

                                                                                             For the
                                                                                        nine-month period
                                                                                        ended September 30,
                                                                                        -------------------
                                                                                          2000        1999
                                                                                        -------      ------
                                                                                            (unaudited)
Cash flows from operating activities:
<S>                                                                                     <C>          <C>
   Net income .......................................................................   $1,098       $1,429
   Adjustments to reconcile net income to net cash provided by operating activities:
      Depreciation and amortization..................................................    1,985        2,035
Change in assets and liabilities--
     Decrease (increase) in assets:
        Patient accounts receivable..................................................       15          277
        Business Services fees receivable............................................      299          352
        Other current assets.........................................................      (54)         567
        Other assets.................................................................      167           81
     Increase (decrease) in liabilities:
         Accounts payable............................................................      651          (96)
         Accrued liabilities.........................................................      427         (131)
         Due to Medical Practices....................................................    1,295         (492)
         Patient deposits............................................................     (124)         350
                                                                                        ------       ------
Net cash provided by operating activities............................................    5,759        4,372
                                                                                        ------       ------

Cash flows used in investing activities:
     Purchase of fixed assets and leasehold improvements.............................     (720)      (2,005)
     Proceeds from sale of fixed assets and leasehold improvements...................       10         --
     Payment for exclusive Business Service rights...................................     (476)        (213)
                                                                                        ------       ------
Net cash used in investing activities................................................   (1,186)      (2,218)
                                                                                        ------       ------

Cash flows used in financing activities:
     Proceeds from issuance of notes payable.........................................     --            150
     Principal repayments on debt....................................................   (1,462)      (1,780)
     Principal repayments under capital lease obligations............................      (97)         (51)
     Repurchase of Common Stock......................................................   (2,383)        (733)
     Dividends paid on Convertible Preferred Stock...................................      (99)         (99)
                                                                                        ------       ------
Net cash used in financing activities................................................   (4,041)      (2,513)
                                                                                        ------       ------

Net increase (decrease) in cash and cash equivalents.................................      532         (359)
Cash and cash equivalents at beginning of period.....................................    3,650        4,241
                                                                                        ------       ------
Cash and cash equivalents at end of period...........................................   $4,182       $3,882
                                                                                        ======       ======

</TABLE>

        See accompanying notes to the consolidated financial statements.

                                      -5-
<PAGE>


                            INTEGRAMED AMERICA, INC.
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (unaudited)


NOTE 1 -- INTERIM RESULTS:

     The  accompanying  unaudited  consolidated  financial  statements have been
prepared in accordance with the instructions to Form 10-Q and,  accordingly,  do
not include all of the information and footnotes  required by generally accepted
accounting  principles  for  complete  financial  statements.  In the opinion of
management,  the accompanying unaudited interim financial statements contain all
adjustments  (consisting only of normal recurring accruals) necessary to present
fairly  the  financial  position  at  September  30,  2000  and the  results  of
operations and cash flows for the interim period  presented.  Operating  results
for the interim  period are not  necessarily  indicative  of results that may be
expected  for the year ending  December  31, 2000.  These  financial  statements
should be read in  conjunction  with the financial  statements and notes thereto
included in the Company's Annual Report on Form 10-K for the year ended December
31, 1999.

     Certain  prior year  amounts  have been  reclassified  to conform  with the
current year presentation.

NOTE 2 -- EARNINGS PER SHARE:

     The  reconciliation  of the  numerators and  denominators  of the basic and
diluted EPS  computations  for the  three-month  and  nine-month  periods  ended
September 30, 2000 and 1999 is as follows (000's  omitted,  except for per share
amounts):
<TABLE>
<CAPTION>

                                                                           For the                    For the
                                                                     three-month period          nine-month period
                                                                     ended September 30,        ended September 30,
                                                                     -------------------        -------------------
                                                                       2000       1999            2000       1999
                                                                     --------   --------        --------   --------
                                                                         (unaudited)                (unaudited)
<S>                                                                    <C>        <C>            <C>        <C>
Numerator
Net Income .......................................................     $ 440      $ 385          $1,098     $1,429
Less: Preferred Stock dividends paid..............................       (33)       (33)            (99)       (99)
                                                                       -----      -----          ------     ------
Net income available to common shareholders.......................     $ 407      $ 352          $  999     $1,330
                                                                       =====      =====          ======     ======

Denominator
Weighted average shares basic.....................................     4,059      4,863           4,199      4,910
Effect of dilutive options and warrants...........................        60        118              62         92
                                                                       -----      -----          ------      -----
Weighted average shares and dilutive potential
    common shares.................................................     4,119      4,981           4,261      5,002
                                                                       =====      =====          ======      =====

Basic EPS.........................................................     $0.10      $0.07          $ 0.24     $ 0.27
Diluted EPS.......................................................     $0.10      $0.07          $ 0.23     $ 0.27
</TABLE>

    For the three and nine-month  periods ended  September 30, 2000,  options to
purchase approximately 607,000 and 532,000 shares of Common Stock, respectively,
at exercise prices ranging from $2.50 to $5.00 per share and from $3.36 to $5.00
per share,  respectively,  were excluded in computing  the diluted  earnings per
share amount  because the  exercise  prices of the options were greater than the
average  market price of the shares of Common  Stock,  therefore,  causing these
options to be  antidilutive.  For both the three and  nine-month  periods  ended
September 30, 2000,  the effect of the assumed  exercise of warrants to purchase
approximately  103,000  shares of Common Stock at exercise  prices  ranging from
$4.12 to $8.54 per share were  excluded in  computing  the diluted  earnings per
share amount  because the exercise  prices of the warrants were greater than the
average  market price of the shares of Common  Stock,  therefore,  causing these
warrants to be antidilutive.

                                      -6-

<PAGE>
                            INTEGRAMED AMERICA, INC.
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (unaudited)


    For the three and nine-month  periods ended  September 30, 1999,  options to
purchase approximately 403,000 and 429,000 shares of Common Stock, respectively,
at  exercise  prices  ranging  from  $4.00 to $5.00 per share were  excluded  in
computing the diluted  earnings per share amount because the exercise  prices of
the options where greater than the average  market price of the shares of Common
Stock, therefore,  causing these options to be antidilutive.  For both the three
and  nine-month  periods  ended  September  30, 1999,  the effect of the assumed
exercise of warrants to purchase  approximately 75,000 shares of Common Stock at
exercise prices ranging from $4.94 to $8.54 per share were excluded in computing
the  diluted  earnings  per share  amount  because  the  exercise  prices of the
warrants  were  greater  than the average  market  price of the shares of Common
Stock, therefore, causing these warrants to be antidilutive.

                                      -7-
<PAGE>



Item 2.  Management's Discussion and Analysis of Financial Condition and
         Results of Operations

     The following  discussion and analysis  should be read in conjunction  with
the  consolidated  financial  statements  and  notes  thereto  included  in this
quarterly  report and with the Company's Annual Report on Form 10-K for the year
ended December 31, 1999.

Results of Operations

     The following table shows the percentage of revenues represented by various
expense  and  other  income  items  reflected  in  the  Company's   Consolidated
Statements of Operations.
<TABLE>
<CAPTION>

                                                                    For the                For the
                                                              three-month period      nine-month period
                                                              ended September 30,    ended September 30,
                                                              -------------------    -------------------
                                                                2000       1999       2000         1999
                                                              -------     -------    -------      ------
                                                                  (unaudited)            (unaudited)


<S>                                                             <C>        <C>         <C>        <C>
         Revenues, net......................................    100.0%     100.0%      100.0%     100.0%
         Costs of services incurred:
              Employee compensation and related expenses....     36.7       39.0        37.9       38.8
              Direct materials..............................     22.1       15.0        20.1       12.3
              Occupancy costs...............................      5.6        6.5         5.9        8.0
              Depreciation..................................      2.1        3.4         2.4        3.0
              Other expenses................................     17.1       16.0        18.3       16.2
                                                                -----      -----       -----      -----
              Total costs of services.......................     83.6       79.9        84.6       78.3
         Contribution.......................................     16.4       20.1        15.4       21.7
         General and administrative expenses................     11.1       13.6        10.4       13.7
         Amortization of intangible assets..................      1.5        2.3         1.5        2.3
         Interest income....................................     (0.4)      (0.4)       (0.3)      (0.3)
         Interest expense...................................      0.7        1.0         0.8        1.1
                                                                -----      -----       -----      -----
              Total other expenses..........................     12.9       16.5        12.4       16.8
                                                                -----      -----       -----      -----
         Income before income taxes.........................      3.5        3.6         3.0        4.9
         Provision for income taxes.........................      0.5        0.4         0.4        0.6
                                                                -----      -----       -----      -----
         Net income.........................................      3.0%       3.2%        2.6%       4.3%
                                                                =====      =====       =====      =====
</TABLE>

   Three Months Ended September 30, 2000 Compared to Three Months Ended
   September 30, 1999

     Revenues for the quarter ended September 30, 2000 were approximately  $14.8
million as  compared  to  approximately  $11.9  million  for the  quarter  ended
September 30, 1999, an increase of 24.9%. Approximately 38.7% of the increase is
attributable  to same market  growth in reimbursed  costs and Business  Services
fees  in  the  Reproductive  Science  Centers,  offset  by  the  elimination  of
terminated Business Services  contracts.  Approximately 61.3% of the increase is
attributable to new businesses  started subsequent to the third quarter of 1999.
Same market  growth in revenues  was  principally  attributable  to increases in
patient  volume.  The same  market  increase in revenues  was  comprised  of the
following:  (i) an  approximate  $1,260,000  increase  in  reimbursed  costs  of
services  associated  with the  increased  patient  volume;  (ii) an increase of
$411,000 in the Company's  Business  Services fees derived from the Reproductive
Science  Centers'  net  revenue  and/or   earnings;   (iii)  $2.1  million  from
pharmaceutical  sales;  (iv) offset by the net effect of the  elimination of the
Walter Reed Medical Center service agreement and the decline in revenue from our
single remaining hospital contract of $830,000.

     Total costs of services as a percentage of revenues were 83.6% in the third
quarter  of 2000,  compared  to  79.9%  in the  third  quarter  of 1999.  Direct
materials and other  expenses  increased as a percentage of revenues,  primarily
due to the  cost  of  products  sold  and  administrative  costs  at  IntegraMed
Pharmaceutical Services.

                                      -8-
<PAGE>

     Contribution was  approximately  $2.4 million in the third quarter of 2000,
approximately  the same as in the  third  quarter  of 1999.  While  same  period
revenues grew significantly,  contribution remained at the same dollar level and
declined as a percentage of revenues due to the decline in higher margin revenue
from the single remaining  hospital  contract and the growth of the lower margin
pharmaceutical revenue.

     General and administrative  expenses were approximately $1.6 million in the
third quarter of 2000,  approximately  the same as in the third quarter of 1999.
As a percentage of revenue,  general and  administrative  expenses  decreased to
11.1% from 13.6% due to planned decreases in staffing at the Company's corporate
headquarters.

     Amortization of intangible assets was $216,000 in the third quarter of 2000
as  compared  to  $274,000  in the  third  quarter  of 1999.  This  decrease  is
attributable to the termination of single  physician  practices  during the 1999
calendar year.

     Interest  income for the third  quarter of 2000  increased  to $56,000 from
$46,000 for the third quarter of 1999,  due to higher cash balances and interest
earned on  advances  made to certain  Reproductive  Science  Centers  for office
expansions. Interest expense for the third quarter of 2000 decreased to $109,000
from $121,000 in the third  quarter of 1999,  due to a decrease in notes payable
to the Company's  financial  institution  for its revolving line of credit and a
decrease in notes payable to Medical  Providers for exclusive  Business  Service
rights.

     The provision for income taxes increased to $81,000 in the third quarter of
2000  from  $45,000  in the  third  quarter  of 1999 due to  reduced  state  net
operating loss carryforwards.

   Nine Months Ended September 30, 2000 Compared to Nine Months Ended
   September 30, 1999

     Revenues for the nine months ended  September  30, 2000 were  approximately
$41.9  million as compared to  approximately  $33.3  million for the nine months
ended  September  30,  1999,  an increase of 26.1%.  Approximately  43.0% of the
increase is attributable to same market growth in reimbursed  costs and Business
Service fees in the Reproductive  Science Centers,  offset by the elimination of
terminated Business Services  contracts.  Approximately 57.0% of the increase is
attributable  to new  businesses  that were started  later in 1999.  Same market
growth in revenues was principally  attributable to increases in patient volume.
The same market growth increase in revenues was comprised of the following:  (i)
an approximate $5.3 million  increase in reimbursed  costs of services;  (ii) an
increase of $100,000 in the  Company's  Business  Services fees derived from the
Reproductive  Science Centers' net revenue and/or  earnings;  (iii) $5.9 million
from  pharmaceutical  sales;  (iv)  offset by a decrease  of $2.6  million  from
termination  of the Walter  Reed  Medical  Center  agreement  and the decline in
revenue from the single remaining hospital contract.

     Total costs of services as a percentage  of revenues  were 84.6% during the
first nine months of 2000,  compared to 78.3% in the same period of 1999. Direct
materials  increased as a percentage  of revenues,  primarily due to the cost of
products sold at IntegraMed Pharmaceutical Services. This increase was partially
offset by a reduction in expenses  associated with the donor egg program related
to the hospital contract.

                                      -9-
<PAGE>

     Contribution was approximately $6.5 million during the first nine months of
2000 as compared to $7.2  million  during the same period of 1999, a decrease of
approximately  10.3%.  This  decrease is the result of the decline in the higher
margin  revenue from the single  remaining  hospital  contract and the growth of
lower margin pharmaceutical revenue.

     General and administrative  expenses for the first nine months of 2000 were
approximately  $4.4  million as compared to  approximately  $4.5 million for the
first nine months of 1999,  a decrease of 2.7%.  As a  percentage  of  revenues,
general and  administrative  expenses  decreased to approximately  10.4% for the
first nine months of 2000 from approximately  13.7% during the first nine months
of 1999. The decrease is primarily attributable to planned staffing decreases at
the corporate office.

     Amortization of intangible assets was $650,000 for the first nine months of
2000 as  compared  to  $779,000  during the same  period of 1999,  a decrease of
16.6%.  This decrease was  attributable to the  termination of single  physician
practices  and the  write-off of the related  intangible  assets during the 1999
calendar year.

     Interest  income for the first nine  months of 2000  increased  to $141,000
from  $88,000  for the same  period of 1999,  due to a higher  cash  balance and
financing proceeds from Reproductive Science Center build-outs. Interest expense
for the first nine months of 2000 decreased to $328,000 from $382,000 during the
same period of 1999, due to a decrease in notes payable to Medical Providers for
exclusive  Business Services rights,  and scheduled  repayments on the Company's
main credit line.

     The  provision  for income  taxes  decreased to $165,000 for the first nine
months of 2000 from  $217,000  for the first nine  months of 1999 due to reduced
contribution amounts, as the effective tax rate remained fairly constant.

Liquidity and Capital Resources

     Historically,  the Company has financed its  operations  primarily  through
sales of equity securities.  More recently, the Company has commenced using bank
financing for working capital and acquisition purposes.  The Company anticipates
that its acquisition and product  development  strategy will continue to require
substantial  capital  investment.  Capital  is  needed  not only for  additional
acquisitions, but also for the effective integration, operation and expansion of
the Company's existing  Reproductive  Science Centers as well as the development
of new products and services.

     At September  30, 2000,  the Company had working  capital of  approximately
$4.7  million,  approximately  $4.2 million of which  consisted of cash and cash
equivalents,  compared  to working  capital  of  approximately  $5.7  million at
December 31,  1999,  approximately  $3.7 million of which  consisted of cash and
cash equivalents.  The net decrease in working capital at September 30, 2000 was
principally  due to the  repurchase of 752,250  shares of the  Company's  Common
Stock for an aggregate purchase price of $2.4 million.

     The Company anticipates that its single remaining hospital contract,  which
is with the  hospital-based  Institute of  Reproductive  Medicine and Science of
Saint Barnabas Medical Center in New Jersey, will expire and will not be renewed
at  the  end  of  2001,  at the  latest.  Recently,  the  Company  has  received
correspondence  from counsel to Saint  Barnabas  Medical  Center  indicating the
Medical  Center's  desire to terminate the contract as early as January 1, 2001.
The  Company  would  be  entitled  to   compensation   for  damages  from  early
termination,  however,  the Medical Center has indicated that it believes it has
overpaid  the  Company  by more than $1.1  million  since the  inception  of the
contract.  The Company  strongly  believes it has not been  overpaid.  It is too
early to determine the ultimate outcome of these events. Annualized revenues and
contribution  from that contract  approximate  $2.85 million and $1.47  million,
respectively.

     The Company is coming under increased  pressure from the Medical  Practices
associated with its Reproductive Science Centers to reduce the Business Services
fees  associated  with the  Reproductive  Science  Centers' net revenues  and/or
earnings.  The Company is unable to determine at this time the impact and amount
of such possible reductions in income.

     The  Company has been unable to add any new  Reproductive  Science  Centers
within the last two years due to  changing  market  conditions.  The  Company is
adjusting its service and product offerings to what it believes will be accepted
in the market.  There is no assurance that the Company's new service and product
offerings will be successful.

       The  Company  expects  its cash flows  from  operating  activities  to be
sufficient  to fund  its  needs  for  asset  acquisition,  product  and  service
development,  debt repayments and Common Stock  repurchase  program for the next
year.

                                      -10-
<PAGE>

Forward Looking Statements

     This Form 10-Q and discussions and/or announcements made by or on behalf of
the Company, contain certain forward-looking  statements regarding events and/or
anticipated  results  within the  meaning of the safe harbor  provisions  of the
Private  Securities  Litigation  Reform  Act of 1995,  the  attainment  of which
involve  various  risks and  uncertainties.  Forward-looking  statements  may be
identified by the use of forward-looking terminology such as, may, will, expect,
believe, estimate,  anticipate,  continue, or similar terms, variations of those
terms or the negative of those terms.  The Company's  actual  results may differ
materially from those described in these  forward-looking  statements due to the
following factors:  the Company's ability to acquire additional business service
agreements,  including the  Company's  ability to raise  additional  debt and/or
equity  capital to  finance  future  growth,  the loss of  significant  business
service agreement(s),  the profitability or lack thereof at Reproductive Science
Centers  serviced by the Company,  increases in overhead due to  expansion,  the
exclusion of infertility  and ART services from insurance  coverage,  government
laws and regulations regarding health care, changes in managed care contracting,
the timely development of and acceptance of new infertility,  ART and/or genetic
technologies and techniques.

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

         Not applicable.
                                      -11-
<PAGE>

Part II -         OTHER INFORMATION

     Item 1.      Legal Proceedings.
                     None;  no  material  developments  in  previously  reported
                     matters.

     Item 2.      Changes in Securities.
                     None.

     Item 3.      Defaults Upon Senior Securities.
                     None.

     Item 4.      Submission of Matters to Vote of Security Holders.
                     None.

     Item 5.      Other Information.
                     None.

     Item 6.      Exhibits and Reports on Form 8-K.
                     (a)    Exhibits
                            See Index to Exhibits on page 14.

                     (b)    Reports on Form 8-K
                            Pursuant  to  Regulation  FD,   Registrant's   press
                            release  dated  November  1, 2000 was filed with the
                            Securities and Exchange Commission on Form 8-K.

                                      -12-
<PAGE>







                                   SIGNATURES


         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                                INTEGRAMED AMERICA, INC.
                                                (Registrant)




Date:    November 13, 2000                    By:/s/John W. Hlywak, Jr.
                                                 ----------------------
                                                 John W. Hlywak, Jr.
                                                 Senior Vice President and
                                                 Chief Financial Officer
                                                 (Duly Authorized Officer and
                                                 Principal Financial and
                                                 Accounting Officer)

                                      -13-
<PAGE>


                                INDEX TO EXHIBITS

Exhibit
Number                                Exhibit
-------                               -------

10.88 (c)     --  Amendment No. 1 dated as of October 1, 2000 to the  Management
                  Agreement  dated as of July 1, 1999 by and between  IntegraMed
                  America, Inc. and MPD Medical Associates, P.C.

27            --  Financial Data Schedule

99.1              Registrant's Press Release dated November 1, 2000 (1)

---------------------------------------

(1)               Filed as Exhibit with identical exhibit number to Registrant's
                  Report on Form 8-K dated November 1, 2000.

                                      -14-